Cargando…
EUCAST Susceptibility Testing of Isavuconazole: MIC Data for Contemporary Clinical Mold and Yeast Isolates
Isavuconazole is the newest medical azole. We investigated EUCAST MICs for isavuconazole and seven comparators against 1,498 contemporary isolates (2016 to 2017). EUCAST susceptibility testing was performed. Isavuconazole MICs >2 dilution steps above the modal MIC were regarded as non-wild type f...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Microbiology
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6535523/ https://www.ncbi.nlm.nih.gov/pubmed/30910898 http://dx.doi.org/10.1128/AAC.00073-19 |
_version_ | 1783421581647675392 |
---|---|
author | Jørgensen, Karin Meinike Astvad, Karen Marie Thyssen Hare, Rasmus Krøger Arendrup, Maiken Cavling |
author_facet | Jørgensen, Karin Meinike Astvad, Karen Marie Thyssen Hare, Rasmus Krøger Arendrup, Maiken Cavling |
author_sort | Jørgensen, Karin Meinike |
collection | PubMed |
description | Isavuconazole is the newest medical azole. We investigated EUCAST MICs for isavuconazole and seven comparators against 1,498 contemporary isolates (2016 to 2017). EUCAST susceptibility testing was performed. Isavuconazole MICs >2 dilution steps above the modal MIC were regarded as non-wild type for species without EUCAST epidemiological cutoff values (ECOFFs). CYP51A sequencing was performed when relevant. Pearson correlation analysis was adopted for comparing activity. Aspergillus accounted for 90% of mold and Candida accounted for 97% of yeast isolates. Thirty (9.3%) Aspergillus fumigatus isolates were classified as resistant, and 10 (3.1%) were classified as non-wild type. Thirteen (4%) were cross-resistant to other mold-active azoles. Target gene alterations were found in 10 (76.9%) isolates, including 4 (30.8%) of environmental origin (TR(34)/L98H [n = 3] and Trip(34)(3)/L98H [n = 1]). Six Aspergillus terreus isolates were resistant, including two (17%) with MICs of >2 mg/liter and M217I alterations. Modal MICs/MIC(50)s (milligrams per liter) against Candida spp. were ≤0.004/≤0.004 for C. albicans and C. dubliniensis, 0.008/0.008 for C. tropicalis, 0.016/0.016 for C. parapsilosis, 0.06/0.06 for C. glabrata, and 0.125/0.125 for C. krusei. A non-wild-type phenotype was observed for 6.6% of isolates (C. glabrata [11.8%] and C. tropicalis [12.3%], specifically). All of these isolates were nonsusceptible/non-wild type to fluconazole (96.1%) or voriconazole (86.2%). Low MICs were found for several other species, except Scedosporium apiospermum and Fusarium. The best correlation was found between isavuconazole and voriconazole overall but for A. terreus and Mucorales to itraconazole and posaconazole, respectively. Isavuconazole displayed broad in vitro activity. Acquired resistance was infrequent except in A. terreus, C. glabrata, and C. tropicalis and, when present, was associated with cross-resistance to other azoles. Revising the EUCAST breakpoints for A. fumigatus (defining an MIC of 2 mg/liter as intermediate [“I”]) would minimize major errors. |
format | Online Article Text |
id | pubmed-6535523 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | American Society for Microbiology |
record_format | MEDLINE/PubMed |
spelling | pubmed-65355232019-06-03 EUCAST Susceptibility Testing of Isavuconazole: MIC Data for Contemporary Clinical Mold and Yeast Isolates Jørgensen, Karin Meinike Astvad, Karen Marie Thyssen Hare, Rasmus Krøger Arendrup, Maiken Cavling Antimicrob Agents Chemother Susceptibility Isavuconazole is the newest medical azole. We investigated EUCAST MICs for isavuconazole and seven comparators against 1,498 contemporary isolates (2016 to 2017). EUCAST susceptibility testing was performed. Isavuconazole MICs >2 dilution steps above the modal MIC were regarded as non-wild type for species without EUCAST epidemiological cutoff values (ECOFFs). CYP51A sequencing was performed when relevant. Pearson correlation analysis was adopted for comparing activity. Aspergillus accounted for 90% of mold and Candida accounted for 97% of yeast isolates. Thirty (9.3%) Aspergillus fumigatus isolates were classified as resistant, and 10 (3.1%) were classified as non-wild type. Thirteen (4%) were cross-resistant to other mold-active azoles. Target gene alterations were found in 10 (76.9%) isolates, including 4 (30.8%) of environmental origin (TR(34)/L98H [n = 3] and Trip(34)(3)/L98H [n = 1]). Six Aspergillus terreus isolates were resistant, including two (17%) with MICs of >2 mg/liter and M217I alterations. Modal MICs/MIC(50)s (milligrams per liter) against Candida spp. were ≤0.004/≤0.004 for C. albicans and C. dubliniensis, 0.008/0.008 for C. tropicalis, 0.016/0.016 for C. parapsilosis, 0.06/0.06 for C. glabrata, and 0.125/0.125 for C. krusei. A non-wild-type phenotype was observed for 6.6% of isolates (C. glabrata [11.8%] and C. tropicalis [12.3%], specifically). All of these isolates were nonsusceptible/non-wild type to fluconazole (96.1%) or voriconazole (86.2%). Low MICs were found for several other species, except Scedosporium apiospermum and Fusarium. The best correlation was found between isavuconazole and voriconazole overall but for A. terreus and Mucorales to itraconazole and posaconazole, respectively. Isavuconazole displayed broad in vitro activity. Acquired resistance was infrequent except in A. terreus, C. glabrata, and C. tropicalis and, when present, was associated with cross-resistance to other azoles. Revising the EUCAST breakpoints for A. fumigatus (defining an MIC of 2 mg/liter as intermediate [“I”]) would minimize major errors. American Society for Microbiology 2019-05-23 /pmc/articles/PMC6535523/ /pubmed/30910898 http://dx.doi.org/10.1128/AAC.00073-19 Text en Copyright © 2019 Jørgensen et al. https://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Susceptibility Jørgensen, Karin Meinike Astvad, Karen Marie Thyssen Hare, Rasmus Krøger Arendrup, Maiken Cavling EUCAST Susceptibility Testing of Isavuconazole: MIC Data for Contemporary Clinical Mold and Yeast Isolates |
title | EUCAST Susceptibility Testing of Isavuconazole: MIC Data for Contemporary Clinical Mold and Yeast Isolates |
title_full | EUCAST Susceptibility Testing of Isavuconazole: MIC Data for Contemporary Clinical Mold and Yeast Isolates |
title_fullStr | EUCAST Susceptibility Testing of Isavuconazole: MIC Data for Contemporary Clinical Mold and Yeast Isolates |
title_full_unstemmed | EUCAST Susceptibility Testing of Isavuconazole: MIC Data for Contemporary Clinical Mold and Yeast Isolates |
title_short | EUCAST Susceptibility Testing of Isavuconazole: MIC Data for Contemporary Clinical Mold and Yeast Isolates |
title_sort | eucast susceptibility testing of isavuconazole: mic data for contemporary clinical mold and yeast isolates |
topic | Susceptibility |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6535523/ https://www.ncbi.nlm.nih.gov/pubmed/30910898 http://dx.doi.org/10.1128/AAC.00073-19 |
work_keys_str_mv | AT jørgensenkarinmeinike eucastsusceptibilitytestingofisavuconazolemicdataforcontemporaryclinicalmoldandyeastisolates AT astvadkarenmariethyssen eucastsusceptibilitytestingofisavuconazolemicdataforcontemporaryclinicalmoldandyeastisolates AT harerasmuskrøger eucastsusceptibilitytestingofisavuconazolemicdataforcontemporaryclinicalmoldandyeastisolates AT arendrupmaikencavling eucastsusceptibilitytestingofisavuconazolemicdataforcontemporaryclinicalmoldandyeastisolates |